Health Care Delivery

Emerging evidence suggests that fibroblast growth factor 21 (FGF21) could play a future part in the treatment of metabolic dysfunction-associated steatohepatitis (MASH).

This year's report demonstrates the potential impact of automated processes on medical and dental industry spending, with projected savings amounting to $20 billion.

A rituximab and lenalidomide combination for treating non-Hodgkin lymphoma (NHL) could play a greater role in future clinical trials.

Antoine Keller, MD, founded HeartSense with the purpose of uncovering and addressing the cardiovascular needs of rural, often underserved communities.

The Center on Health Equity & Access strives to improve health care delivery and outcomes by addressing disparities through education, training, frontline insights, and evidence-based approaches.

The large UK Biobank study finds depression a significant risk predictor for developing chronic conditions such as osteoarthritis, hypertension, and gastro-oesophageal reflux disease.

The Senate voted 52-48 to confirm Robert F. Kennedy Jr as secretary of HHS, setting up the vaccine skeptic to carry out major changes in pursuit of his Make America Healthy Again agenda.

New data show states with abortion bans saw increased infant deaths, with the greatest impact on Black infants and congenital anomaly-related deaths.

Reducing intravenous (IV) isatuximab delivery from 75 minutes to 30 minutes could provide a wealth of benefits to patients with multiple myeloma (MM) and health care systems alike.

Researchers have developed an evaluation protocol index to optimize postoperative recovery.

Telehealth disparities are driven by more than language barriers, according to experts outlining systemic factors and solutions in new research.

Gladys Antelo-Allen, ​​associate director of education and training at Camden Coalition, dives into the foundational skills in complex care that can enhance provider education and facilitate trusting patient-provider relationships.

Joshua Kaufman, MD, medical director of Behavioral Health and Medical Integration at Capital District Physicians' Health Plan, outlines the progression of treatment approaches for comorbid schizophrenia and substance use disorder.

Persistent care barriers may lead patients with inflammatory bowel disease (IBD) to ration medication or skip doses. The Crohn’s & Colitis Congress 2025 explored these access issues as well as the potential cardiovascular complications related to IBD therapies.

Patients with mild atopic dermatitis who reported nighttime scratching experienced relief when they used an artificial intelligence (AI)-powered wearable sensor that delivered haptic feedback on sleep behaviors.

George Jones of UpScript Health discusses telemedicine's evolution from basic e-prescribing to real-time video consultations, expanding treatment beyond primary care.

Results from the AZALEA-TIMI 71 phase 2 trial showed great promise for abelacimab to transform care for high-risk patients with atrial fibrillation.

The number of psychiatrists submitting more than 10 claims to Medicare Part B decreased by 16.8% from 2014 to 2022.

“To error is human, and also to error is in machine learning,” said Debra Patt, MD, PhD, MBA, MPH.

Expert perspectives shed light on complex care and prior authorization. Despite DEI rollbacks under the new administration, disparities are still prevalent in health care and research.

Joshua Kaufman, MD, medical director of Behavioral Health and Medical Integration at Capital District Physicians' Health Plan, discusses the bidirectional relationship between schizophrenia and substance use disorders in an interview.

During the unwinding of continuous Medicaid provisions, 8.7% of pediatric patients at community-based health organizations became uninsured, with higher rates among older children, females, and those with chronic medical conditions.

Dementia was more prevalent in older patients with some cancer types, and comorbid dementia in this population was associated with unplanned or unnecessary hospitalization.

The removal of FDA guidance on clinical trial diversity and related anti–diversity, equity, and inclusion (DEI) actions may hinder progress toward equitable health care, impacting workforce diversity, patient outcomes, and research.

Better access and capability scores were associated with integrated practice ownership and participation in accountable care organizations.